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Primary cutaneous B-cell lymphoma: A clinically 
homogeneous entity? 
Nicola Pimpinelli, MD, PhD, a Marco Santucci, MD, c Moira Mori, MD, a 
Carlo Vallecchi, MD, b and Benvenuto Giannotti, MD a Florence, Italy 
Primary cutaneous B-cell lymphomas (CBCLs) 
represent a distinct group of lymphoproliferative 
diseases that have to be distinguished from non- 
Hodgkin's B-cell lymphomas with secondary 
cutaneous involvement and from cutaneous B-cell 
pseudolymphomas. 
PRIMARY CBCL 
Although several cases of primary CBCL had 
been reported by 1978,1-4 studies published before 
1987 did not distinguish between primary and sec- 
ondary/concurrent cutaneous presentations. 5-1° 
This was based on the common opinion that cuta- 
neous lymphomas other than mycosis fungoides 
represented dissemination from nodal disease. On 
the other hand, B-cell cutaneous disorders charac- 
terized clinically by good response to local treat- 
ment and favorable prognosis and histologically 
by cytologic polymorphism (small and large cells) 
and the presence of lymphoid follicles were 
regarded as reactive processes (pseudolym- 
phomas). 4,11-14 Since 1987, studies of patients 
with primary CBCL have been published, 15-18 in 
which the patients were carefully selected on the 
basis of (1) primary cutaneous presentation, (2) no 
evidence of extracutaneous di ease, and (3) light 
chain monoclonal restriction or negative staining 
for surface immunoglobulins onCD20 ÷, CD22 + B 
cells in frozen sections or immunoglobulin heavy 
chain gene rearrangement, or both. These patients 
had characteristic linical features: localized 
plaques, nodules or tumors, often surrounded by 
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papules and slightly infiltrated, sometimes figu- 
rate plaques, present for months to many years 
before the appearance of larger lesions. These 
lesions usually have a regional distribution on the 
trunk (51.7% in our series of 154 patients to date) 
and head and neck (23.1%) and, to a lesser extent, 
on the limbs (13.3%). Skin lesions are highly 
responsive to orthovolt radiotherapy 18-21 (96.9% 
complete remissions in our series), either at pre- 
sentation or after relapse. Despite cutaneous 
relapses (25.8% in our series), primary CBCLs 
have only a slight tendency to extracutaneous 
spread (9.1% in our series) and an excellent prog- 
nosis (96.2% 5-year and 95.5% 10-year survival 
in our series). However, it is now clear that a 
favorable clinical course and a "low-grade" histo- 
logic picture are incorrect and unreliable criteria 
to differentiate between CBCL and pseudolym- 
phomas. The only reliable tool is the demonstra- 
tion of B-cell monoclonality by immunohisto- 
chemistry and/or molecular analysis by Southern 
blotting and the polymerase chain reaction. 18,22-28 
The conclusion that most primary CBCLs have 
highly distinctive clinical features, first proposed 
by the Dutch Cutaneous Lymphoma Working 
Group (DCLWG) 15 and two Italian groups 
(Milan 16 and Florence 17,18) and later ratified at the 
First International Symposium on Cutaneous 
Lymphoma in 1988, 24,29,30 is now shared by other 
groups worldwide, particularly in Europe. 
Nevertheless, an interesting and stimulating 
debate is ongoing about the classification, histo- 
genesis, and pathogenesis of primary CBCL. 
There is consensus concerning the difficulty in 
categorizing primary CBCL according to the 
updated Kiel classification 31 or to the Revised 
European-American Lymphoma (R.E.A.L.) clas- 
sification. 32 However, the proposed solutions are 
different. 
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CLASSIFICATION OF PRIMARY CBCL: THE 
DCLWG VIEW 
The DCLWG proposed classifying primary 
CBCL into clinically low-grade (follicular center 
cell [FCC] lymphoma nd immunocytoma [IC]) 
and rare/undefined types. 33 Primary cutaneous 
FCC lymphoma nd IC, which affect more than 
90% of all patients with a definite diagnosis of pri- 
mary CBCL, share a good response to radiothera- 
py and a generally excellent prognosis that is 
much better than morphologically similar lym- 
phomas in lymph nodes. Primary cutaneous FCC 
lymphoma ls,34 is characterized by localized infil- 
trative lesions on the trunk and scalp and, in elder- 
ly patients, on the legs. Histologic examination 
reveals that it is composed of FCCs, usually a 
mixture of centrocytes ( mall and large cleaved 
FCC) and centroblasts (large FCC with prominent 
nucleoli). It has a chronic course, is highly sensi- 
tive to radiotherapy, and has a good prognosis, 
with the exception of a recently defined subset 
(large-cell FCC lymphoma of the leg), which pre- 
dominantly affects elderly patients and has an 
intermediate prognosis. 35 Primary cutaneous IC 36 
is characterized clinically by one or several, often 
deeply seated nodules or tumors, almost without 
exception on arms or legs, and has an excellent 
prognosis. Histologic examination reveals lym- 
phoplasmacytoid/plasma cellsat the periphery of 
the nodular infiltrates, different from the dispersed 
distribution of the same cells in secondary cuta- 
neous IC 36 and nodal IC. 31 
AN ALTERNATIVE VIEW: THE SALT/MALT 
HYPOTHESIS 
Since 1988, at the International Symposium on 
Cutaneous Lymphoma held in Copenhagen 29 and 
later based on our series of patients, 18 we stressed 
the close similarities between primary CBCL, 
morphologically classifiable as FCC lymphomas 
or IC, and B-cell lymphomas of the so-called 
mucosa-associated lymphoid tissue (MALT lym- 
phomas). 37 These have nonaggressive clinical 
behavior, with mostly localized disease, a good 
response to orthovolt radiotherapy, only a slight 
tendency to extracutaneous spread, and an excel- 
lent prognosis. In our experience 18and in that of 
other groups (Berti E., unpublished ata), a dis- 
tinct subset of elderly patients characterized by 
lesion location on the legs, large-cell histology 
findings and intermediate prognosis 35 is not iden- 
tifiable. Histologic features of primary CBCL 
include a characteristic polymorphism of the neo- 
plastic cellular infiltrate, with cells resembling 
small centrocytes ("centrocyte-like c lls"37), large 
anaplastic entrocytes and centroblasts of differ- 
ent subtypes, plasma and/or plasmacytoid cells, 
and immunoblasts. The relative proportion of each 
of these cell types and the extent of the reactive T- 
cell and B-cell infiltrate (often represented by 
reactive lymphoid follicles) are highly variable 
according to the size, age, and growth rate of 
lesions and do not have any significant correlation 
with the overall evolution of the disease. 18 A 
prevalence ofcentrocyte-like B cells, plasma/lym- 
phoplasmacytoid cells, and an abundant, often 
overwhelming infiltrate of small lymphocytes 
(mostly T cells) are characteristic features of early 
lesions, whereas a clear-cut prevalence of large 
blastlike cells and a scarce reactive infiltrate are 
characteristic of late lesions. It is typical to find 
different histologic features (low-grade and high- 
grade) in different lesions in the same patient and 
even in different portions of the same lesion. 18 
MALT lymphomas and primary CBCLs also 
share multiphasic histologic features, with the var- 
ious cell types often grouped together rather than 
intermingled; lymphoepithelial lesions, although 
this is an occasional finding in primary CBCL; 
phenotype of neoplastic B cells (CD5-, CD10-); 
and genotype of neoplastic B cells, which do not 
show either t(11; 14)/t(14; 18) translocation orbcl- 
1/bcl-2 gene and c-myc oncogene rearrange- 
ments. 23,24,38,39 Bcl-2 expression is never detected 
in B-cell pseudolymphomas 38 and is significantly 
more frequent in secondary CBCL (nodal FCC 
lymphomas with secondary cutaneous involve- 
ment) than in primary CBCL38,39; in addition, the 
relation between bcl-2 expression and bcl-2 gene 
rearrangement is definitely closer in secondary 
CBCL than in primary CBCL. 38,39 These findings 
suggest the possible significance of bcl-2 protein 
expression and bcl-2 genes rearrangement to dif- 
ferentiate between B-cell pseudolymphomas, pri-
mary CBCL, and secondary CBCL. 
The above histologic and, more important, phe- 
notypic/genotypic features led us to hypothesize a 
possible histogenesis from the marginal cell for 
primary CBCL, 40,41 similar to what has been pro- 
posed for MALT lymphomas 37,42 and so-called 
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parafollicular/monocytoid lymphomas. 43 Several 
facts argue against an FCC origin and may be rea- 
sonably interpreted as indicative of origin from 
the marginal cell. This cell type is putatively capa- 
ble of differentiation i to the various cells charac- 
teristic of most primary CBCLs as well as of 
MALT lymphomas and parafollicular/monocytoid 
lymphomas. 44 The facts that primarily argue 
against an FCC origin are as follows: (1) the CD5-, 
CD10-, Leu-8 +/- phenotype of neoplastic B cells; 
(2) the nerve growth factor receptor + (clone 
20.4), CD14-, CD21 +/- phenotype of associated 
dendritic cells45-47; (3) the lack of t(11;14)/ 
t(14;18) chromosomal translocation and bcl- 
1/bcl-2 genes and c-myc oncogene rearrangement; 
and (4) the demonstration, i  a series of cases 
diagnosed as cutaneous FCC lymphomas, of a 
unimodal population of cells with intermediate 
morphometric features, which could not be identi- 
fied as centrocytes, centroblasts, or immuno- 
biasts. 48 Some authors have hypothesized that 
most primary CBCLs are indeed marginal cell 
(parafollicular/monocytoid) lymphomas and that 
that is the reason for their good prognosis as 
opposed to the rare, true FCC lymphomas. 49 
Nevertheless, the striking tendency to remain 
localized and the rare occurrence of bone marrow 
involvement make primary CBCLs and MALT 
lymphomas different from marginal cell (monocy- 
toid/parafollicular) lymphomas and justify their 
designation as distinct entities. Similarly, some 
question the classification of a certain proportion 
of primary CBCLs as cutaneous IC, notwithstand- 
ing the presence of monotypic plasma/lympho- 
plasmacytoid cells. In fact, in the skin the plas- 
ma/lymphoplasmacytoid cellsare generally locat- 
ed at the periphery of the nodular infiltrates and 
differ from the dispersed istribution of the same 
cells in secondary cutaneous IC 36 and nodal IC. 31 
Conversely, in MALT lymphoma the plasma/lym- 
phoplasmacytoid cell monoclonal proliferation 
can be marked and usually surrounds islands of 
centrocyte-like c lls. 43 
The many striking similarities between MALT 
B-cell lymphoma nd primary CBCL suggest that 
most of the latter may be reasonably considered 
the cutaneous equivalent of MALT lymphoma nd 
the neoplastic ounterpart of the acquired B-cell 
skin-associated lymphoid tissue (SALT), 18,49 
which is the development of cutaneous B-cell 
hyperplasia in relation to known stimuli (insect 
bites, tattoos, Borrelia burgdorferi nfection) and 
the potential of some to progress to overt lym- 
phomas. 26,5°,51 For these reasons, we proposed the 
term skin-associated lymphoid tissue (SALT)- 
related B-cell lymphoma. 18,29,4°,41 
These interpretations strongly contrast with 
those of the DCLWG. 52 They state that the mar- 
ginal cell hypothesis only related to "negative" 
criteria and that a reliable "positive" marker is 
currently lacking (a monoclonal ntibody, KiMlp, 
has been recently proposed as a possible diagnos- 
tic tool by the Graz group53,54). For this reason, 
the DCLWG considers their current classification 
of primary CBCL based on the delineation of 
well-defined clinicopathologic entities (FCC lym- 
phoma, with the large-cell variant of the leg, and 
IC, plus other are types) to be the most reliable. 
CONCLUSION 
Primary CBCLs represent a distinct group of 
lymphoproliferative diseases; they have to be 
clearly separated from non-Hodgkin's B-cell lym- 
phomas with secondary cutaneous involvement 
and from cutaneous B-cell pseudolymphomas. 
Most primary CBCLs are characterized by a 
homogeneous clinical presentation and behavior, 
with good response to orthovolt radiotherapy, only 
a slight tendency to extracutaneous spread, and 
excellent prognosis. 33,55 For this reason, bizarre 
terms such as semimalignant ("pseudolymphoma- 
tous") CBCLs 56 have recently been coined. The 
DCLWG strongly suggests classifying these pri- 
mary CBCLs as FCC lymphoma nd IC. 33 In our 
series, the large majority of primary CBCLs have 
a uniform immunophenotype (CD5-, CD10-) and 
genotype (lack of bcl-1/bcl-2 and c-myc gene 
rearrangement) of neoplastic cells, despite a great 
histologic and immunohistologic variability large- 
ly related to the age and growth rate of the skin 
lesions, without any significant correlation with 
the overall evolution of the disease. These similar- 
ities to MALT lymphomas and the evidence for an 
acquired B-cell arm of SALT led us to propose the 
designation of these CBCL as SALT-related B- 
cell lymphomas, 4° a term which encompasses the 
traditional histologic ategories. 
Notwithstanding these different interpretations 
and the debate, continued within the panel of 
experts of the European Organization for 
Research and Treatment of Cancer Cutaneous 
Lymphoma Study Group to establish a consensus 
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classification of primary cutaneous lymphomas 57, 
a simple and clear message should be directed at 
the clinician: a patient with primary CBCL has a 
substantial likelihood of having a localized dis- 
ease that will respond well to nonaggressive treat- 
ment such as orthovolt radiotherapy. Although 
there is a significant risk of relapse, only a small 
minority of these patients will die of their disease. 
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